We found that the Arf-GTPase ARF6, and its downstream effector AMAP1 (also called ASAP1/DDEF1), are often overexpressed in various types of cancer, including PDAC, and closely associated with poor patient survival (145–149). The gene discussed is ASAP1; the disease is cancer.